| Metric | Value (₹ Cr) | Q2 FY26 | Q3 FY25 |
|---|---|---|---|
| Revenue | 22.06 | 19.3% | 27.2% |
| Total Income | 22.36 | 19.8% | 26.6% |
| Expenditure | 18.66 | 38.5% | 23.1% |
| PBT | 3.70 | 28.8% | 47.4% |
| Net Profit | 2.78 | 40.1% | 46.3% |
| OPM | 17.40% | 10.96pp | 6.77pp |
| NPM | 12.42% | 12.44pp | 1.67pp |
| EPS | 2.21 | 41.5% | 36.4% |
Sanjivani Paranteral Ltd. Reports 261.67 Lacs Net Profit for Quarter Ended 31st December 2025
13 Feb 2026 · 13 Feb, 5:31 pm
Summary
Sanjivani Paranteral Ltd. has reported a net profit of 261.67 Lacs for the quarter ended 31st December 2025. The company's revenue from operations stands at 5474.30 Lacs for the same period. Despite an increase in net profit, the Earnings Per Share (EPS) has marginally decreased due to the conversion of warrants into equity shares.
Key Highlights
- 1
Revenue from operations for the quarter ended 31st December 2025 stands at 5474.30 Lacs
- 2
Net profit for the quarter ended 31st December 2025 is 261.67 Lacs
- 3
EPS has marginally decreased due to the conversion of warrants into equity shares
- 4
Company exports approximately 77% of its revenue across 20 countries
- 5
Company has successfully completed stringent regulatory audits for three additional countries
- 6
New IV fluid manufacturing facility in Pune has started commercial dispatches
- 7
The Pune plant already holds a robust forward order book covering the next 90 days
Management Comments
Wani Khemka
Managing Director
The Company has successfully overcome the challenges prevailing in the previous quarter and was able to clock higher revenues. The Compnay is now geared up to demonstrate a study peformance in the coming period. The new, advanced IV fluid manufacturing facility in Pune has started the commercial dispatches during period under review. The plant already holds a robust forward order book covering the next 90 days, with a healthy mix of domestic and export commitments. This facility is a key milestone in strengthening Sanjivani’s presence in both institutional and private-label healthcare segments.
Informational and educational content only. Not investment advice.